An mTORC1‐Dependent Mouse Model for Cardiac Sarcoidosis
Carlos Bueno‐Betí, Clarice X. Lim, Alexandros Protonotarios, Petra Lujza Szabó, Joseph Westaby, Mario Mazic, Mary N. Sheppard, Elijah R. Behr, Ouafa Hamza, Attila Kiss, Bruno K. Podesser, Markus Hengstschläger, Thomas Weichhart, Angeliki Asimaki
Abstract
Background Sarcoidosis is an inflammatory, granulomatous disease of unknown cause affecting multiple organs, including the heart. Untreated, unresolved granulomatous inflammation can lead to cardiac fibrosis, arrhythmias, and eventually heart failure. Here we characterize the cardiac phenotype of mice with chronic activation of mammalian target of rapamycin (mTOR) complex 1 signaling in myeloid cells known to cause spontaneous pulmonary sarcoid‐like granulomas. Methods and Results The cardiac phenotype of mice with conditional deletion of the tuberous sclerosis 2 ( TSC2 ) gene in CD11c + cells (TSC2 fl/fl CD11c‐Cre; termed TSC2 KO ) and controls ( TSC2 fl/fl ) was determined by histological and immunological stains. Transthoracic echocardiography and invasive hemodynamic measurements were performed to assess myocardial function. TSC2 KO animals were treated with either everolimus, an mTOR inhibitor, or Bay11‐7082, a nuclear factor‐kB inhibitor. Activation of mTOR signaling was evaluated on myocardial samples from sudden cardiac death victims with a postmortem diagnosis of cardiac sarcoidosis. Chronic activation of mTORC1 signaling in CD11c + cells was sufficient to initiate progressive accumulation of granulomatous infiltrates in the heart, which was associated with increased fibrosis, impaired cardiac function, decreased plakoglobin expression, and abnormal connexin 43 distribution, a substrate for life‐threatening arrhythmias. Mice treated with the mTOR inhibitor everolimus resolved granulomatous infiltrates, prevented fibrosis, and improved cardiac dysfunction. In line, activation of mTOR signaling in CD68 + macrophages was detected in the hearts of sudden cardiac death victims who suffered from cardiac sarcoidosis. Conclusions To our best knowledge this is the first animal model of cardiac sarcoidosis that recapitulates major pathological hallmarks of human disease. mTOR inhibition may be a therapeutic option for patients with cardiac sarcoidosis.